1228571-16-1 Usage
Description
(S)-5H,6H,7H-cyclopenta[b]pyridin-7-amine is a chiral chemical compound characterized by a cyclic structure that features a pyridine ring fused to a cyclopentane ring. (S)-5H,6H,7H-cyclopenta[b]pyridin-7-amine exhibits a specific 3D arrangement of atoms, which gives it its (S) stereochemistry. The presence of an amine functional group at the 7th position of the cyclopenta[b]pyridine ring classifies it as a primary amine. Its unique structural and stereochemical properties suggest potential applications in medicinal chemistry, particularly for the development of pharmaceuticals and biologically active molecules. (S)-5H,6H,7H-cyclopenta[b]pyridin-7-amine's distinctive attributes make it a promising candidate for further research and potential use in diverse chemical and biological settings.
Uses
Used in Medicinal Chemistry:
(S)-5H,6H,7H-cyclopenta[b]pyridin-7-amine is utilized as a key building block in the synthesis of pharmaceuticals due to its unique cyclic structure and stereochemistry. Its amine functional group allows for further chemical modifications, making it a versatile component in the creation of biologically active molecules.
Used in Drug Development:
In the pharmaceutical industry, (S)-5H,6H,7H-cyclopenta[b]pyridin-7-amine serves as a precursor for the development of new drugs. Its specific stereochemistry and primary amine functionality are advantageous for designing molecules with targeted biological activities, potentially leading to the discovery of novel therapeutic agents.
Used in Biological Research:
(S)-5H,6H,7H-cyclopenta[b]pyridin-7-amine is employed as a research tool in biological studies to investigate the interactions between small molecules and biological targets. Its unique structure and stereochemistry enable it to be used in probing the mechanisms of various biological processes and in the development of targeted therapies.
Overall, the diverse applications of (S)-5H,6H,7H-cyclopenta[b]pyridin-7-amine in medicinal chemistry, drug development, and biological research underscore its potential as a valuable compound for advancing scientific knowledge and improving human health.
Check Digit Verification of cas no
The CAS Registry Mumber 1228571-16-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,8,5,7 and 1 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1228571-16:
(9*1)+(8*2)+(7*2)+(6*8)+(5*5)+(4*7)+(3*1)+(2*1)+(1*6)=151
151 % 10 = 1
So 1228571-16-1 is a valid CAS Registry Number.
1228571-16-1Relevant articles and documents
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication
Skerlj, Renato T.,Bridger, Gary J.,Kaller, Al,McEachern, Ernest J.,Crawford, Jason B.,Zhou, Yuanxi,Atsma, Bem,Langille, Jonathon,Nan, Susan,Veale, Duane,Wilson, Trevor,Harwig, Curtis,Hatse, Sigrid,Princen, Katrien,De Clercq, Erik,Schols, Dominique
body text, p. 3376 - 3388 (2010/09/05)
The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small molecule, orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure-activity relationship (SAR) was determined on the basis of the inhibition of replication of X4 HIV-1 NL4.3 in MT-4 cells. As a result of lead optimization, we identified (S)-N′-((1H-benzo[d]imidazol-2-yl)methyl)- N′-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD070) 2 as a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay. Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 2 and 26 nM, respectively, while remaining noncytotoxic to cells at concentrations exceeding 23 μM. The pharmacokinetics of 2 was evaluated in rat and dog, and good oral bioavailability was observed in both species. This compound represents the first small molecule orally bioavailable CXCR4 antagonist that was developed for the treatment of HIV-1 infection.
SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS
-
Page/Page column 32, (2008/12/04)
Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.
Enzymatic resolution of bicyclic 1-heteroarylamines using Candida antarctica lipase B
Skupinska, Krystyna A.,McEachern, Ernest J.,Baird, Ian R.,Skerlj, Renato T.,Bridger, Gary J.
, p. 3546 - 3551 (2007/10/03)
Candida antarctica lipase B has been used to kinetically resolve a structurally diverse series of bicyclic 1-heteroaryl primary amines by enantioselective acetylation. High yields of either enantiomer could be obtained with excellent enantioselectivity (90-99% ee), while the undesired enantiomer could, in some cases, be recycled by thermal racemization. The absolute stereochemistry of the products was confirmed by an X-ray crystal structure.
